Inovio Presents Data From Phase 1b Trial With INO-4201 As Ebola Booster For RVSV-ZEBOV

(RTTNews) - Inovio (INO) said that data from a Phase 1b trial evaluating INO-4201 as an Ebola booster vaccine candidate for rVSV-ZEBOV (Ervebo) (NCT04906629) was presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases.

Preliminary data showed that INO-4201 was well tolerated and produced a strong immune response. This suggests that a booster dose of IN0-4201 has the potential to extend protection against Ebola and could be an important tool in future Ebola Virus Disease prevention.

INO-4201 is INOVIO's DNA vaccine targeting Zaire Ebola virus (ZEBOV) glycoprotein (GP), designed to prevent ZEBOV infection. INO-4201 encodes for a synthetic consensus antigen that encompasses ZEBOV genetic variability from various outbreak strains to broaden immune coverage for divergent ZEBOV virus variants.

For More Such Health News, visit rttnews.com